AU2019256719A1 - Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers - Google Patents
Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers Download PDFInfo
- Publication number
- AU2019256719A1 AU2019256719A1 AU2019256719A AU2019256719A AU2019256719A1 AU 2019256719 A1 AU2019256719 A1 AU 2019256719A1 AU 2019256719 A AU2019256719 A AU 2019256719A AU 2019256719 A AU2019256719 A AU 2019256719A AU 2019256719 A1 AU2019256719 A1 AU 2019256719A1
- Authority
- AU
- Australia
- Prior art keywords
- nmr
- mhz
- alkyl
- compound
- c4alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660880P | 2018-04-20 | 2018-04-20 | |
| US62/660,880 | 2018-04-20 | ||
| PCT/US2019/028544 WO2019204813A1 (en) | 2018-04-20 | 2019-04-22 | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019256719A1 true AU2019256719A1 (en) | 2020-11-05 |
Family
ID=67139787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019256719A Abandoned AU2019256719A1 (en) | 2018-04-20 | 2019-04-22 | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers |
| AU2019256722A Abandoned AU2019256722A1 (en) | 2018-04-20 | 2019-04-22 | Imidazopyridines useful as mitochondrial uncouplers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019256722A Abandoned AU2019256722A1 (en) | 2018-04-20 | 2019-04-22 | Imidazopyridines useful as mitochondrial uncouplers |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11708376B2 (https=) |
| EP (3) | EP3781165A4 (https=) |
| JP (3) | JP2021523933A (https=) |
| KR (3) | KR20210003831A (https=) |
| CN (3) | CN112262141A (https=) |
| AU (2) | AU2019256719A1 (https=) |
| BR (2) | BR112020021466A2 (https=) |
| CA (2) | CA3097752A1 (https=) |
| IL (2) | IL278070A (https=) |
| MX (2) | MX2020011049A (https=) |
| WO (3) | WO2019204819A1 (https=) |
| ZA (2) | ZA202006295B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11708376B2 (en) * | 2018-04-20 | 2023-07-25 | Virginia Tech Intellectual Properties, Inc. | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers |
| WO2020191503A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4482494A4 (en) * | 2022-02-21 | 2026-02-25 | Univ Colorado Regents | RE-SENSITIZATION OF MULTI-DRUG-RESISTANT GRAM-NEGATIVE (MDR) BACTERIA TO COLISTIN USING IONOPHORES |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2501680A1 (fr) | 1981-03-12 | 1982-09-17 | Elf Aquitaine | Synthese de tetra mercaptides stanniques |
| US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
| JP2668259B2 (ja) * | 1988-02-18 | 1997-10-27 | 塩野義製薬株式会社 | 複素環化合物および抗潰瘍剤 |
| GB2215209B (en) | 1988-03-14 | 1992-08-26 | Osmed Inc | Method and apparatus for biodegradable, osteogenic, bone graft substitute device |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JPH0327172A (ja) | 1989-06-19 | 1991-02-05 | Nissan Chem Ind Ltd | 布の漂白方法 |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| JPH0741461A (ja) * | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
| EP1424072A1 (en) * | 1999-03-03 | 2004-06-02 | Samjin Pharmaceutical Co., Ltd. | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors |
| PL365238A1 (en) * | 2000-02-16 | 2004-12-27 | Neurogen Corporation | Substituted arylpyrazines |
| WO2002020463A2 (en) * | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
| AU2003252478A1 (en) * | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| EP1529531A1 (en) * | 2003-11-04 | 2005-05-11 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| EP1799689A1 (en) | 2004-10-14 | 2007-06-27 | Compass Pharmaceuticals LLC | Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| CA2626220A1 (en) * | 2005-12-21 | 2007-06-28 | Janssen Pharmaceutica N.V. | Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases |
| EP2017277A1 (en) * | 2007-06-29 | 2009-01-21 | 4Sc Ag | Thiophene-imidazopyridines |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| BRPI1013904A2 (pt) * | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| JP6075621B2 (ja) * | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| JP6073343B2 (ja) * | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| KR101481952B1 (ko) * | 2012-04-13 | 2015-01-22 | 한국과학기술연구원 | 신경보호제로서의 유레아 유도체 |
| EP2863910B1 (en) | 2012-06-20 | 2020-03-11 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TW201441203A (zh) | 2012-11-05 | 2014-11-01 | Medeia Therapeutics Ltd | Ｎ－取代４－胺苯酚及對應醌亞胺 |
| CA2917262A1 (en) * | 2013-07-02 | 2015-01-08 | Syngenta Participations Ag | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents |
| KR101428622B1 (ko) * | 2014-01-07 | 2014-08-13 | 국방과학연구소 | 옥사디아졸로 피라진기를 포함하는 화합물 또는 염을 포함하는 리튬 이차 전지용 전극 및 이를 포함하는 리튬 이차 전지 |
| CA2965781A1 (en) * | 2014-10-28 | 2016-05-06 | Shionogi & Co., Ltd. | Heterocyclic derivative having ampk activating effect |
| CA2968299A1 (en) * | 2014-11-18 | 2016-05-26 | Rutgers, The State University Of New Jersey | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
| WO2017151063A1 (en) * | 2016-03-03 | 2017-09-08 | Agency For Science, Technology And Research | Use of furazano[3,4-b]pyrazine derivatives for chemotherapy |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| US11896591B2 (en) * | 2017-05-22 | 2024-02-13 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
| US11708376B2 (en) * | 2018-04-20 | 2023-07-25 | Virginia Tech Intellectual Properties, Inc. | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers |
-
2019
- 2019-04-22 US US17/049,232 patent/US11708376B2/en active Active
- 2019-04-22 KR KR1020207033297A patent/KR20210003831A/ko not_active Withdrawn
- 2019-04-22 KR KR1020207033337A patent/KR102913366B1/ko active Active
- 2019-04-22 CA CA3097752A patent/CA3097752A1/en active Pending
- 2019-04-22 EP EP19789309.2A patent/EP3781165A4/en not_active Withdrawn
- 2019-04-22 US US17/048,897 patent/US20210253594A1/en not_active Abandoned
- 2019-04-22 WO PCT/US2019/028560 patent/WO2019204819A1/en not_active Ceased
- 2019-04-22 BR BR112020021466-3A patent/BR112020021466A2/pt not_active Application Discontinuation
- 2019-04-22 CN CN201980038722.7A patent/CN112262141A/zh active Pending
- 2019-04-22 MX MX2020011049A patent/MX2020011049A/es unknown
- 2019-04-22 AU AU2019256719A patent/AU2019256719A1/en not_active Abandoned
- 2019-04-22 JP JP2021506390A patent/JP2021523933A/ja active Pending
- 2019-04-22 CN CN201980038852.0A patent/CN112261941A/zh active Pending
- 2019-04-22 BR BR112020021469-8A patent/BR112020021469A2/pt not_active Application Discontinuation
- 2019-04-22 US US17/049,145 patent/US20210253538A1/en not_active Abandoned
- 2019-04-22 MX MX2020011050A patent/MX2020011050A/es unknown
- 2019-04-22 KR KR1020207033356A patent/KR102900692B1/ko active Active
- 2019-04-22 WO PCT/US2019/028544 patent/WO2019204813A1/en not_active Ceased
- 2019-04-22 CN CN201980038732.0A patent/CN112262146A/zh active Pending
- 2019-04-22 EP EP19735420.2A patent/EP3781572A1/en active Pending
- 2019-04-22 WO PCT/US2019/028555 patent/WO2019204816A1/en not_active Ceased
- 2019-04-22 JP JP2021506391A patent/JP2021523934A/ja active Pending
- 2019-04-22 JP JP2021506388A patent/JP2021522327A/ja active Pending
- 2019-04-22 EP EP19735421.0A patent/EP3781567B1/en active Active
- 2019-04-22 AU AU2019256722A patent/AU2019256722A1/en not_active Abandoned
- 2019-04-22 CA CA3097751A patent/CA3097751A1/en active Pending
-
2020
- 2020-10-09 ZA ZA2020/06295A patent/ZA202006295B/en unknown
- 2020-10-09 ZA ZA2020/06296A patent/ZA202006296B/en unknown
- 2020-10-15 IL IL278070A patent/IL278070A/en unknown
- 2020-10-15 IL IL278069A patent/IL278069A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019256719A1 (en) | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers | |
| RU2641291C2 (ru) | Частично насыщенное азотсодержащее гетероциклическое соединение | |
| EP2576547B1 (de) | Substituierte 5-fluor-1h-pyrazolopyridine und ihre verwendung | |
| EP3390374A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| UA109295C2 (uk) | Похідні гетероарилсульфонамідів, їх одержання і застосування для лікування людини | |
| EP3630115B1 (en) | Compositions and methods for preparing and using mitochondrial uncouplers | |
| KR20190115014A (ko) | 하이드로카르빌설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 | |
| AU2009247250A1 (en) | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | |
| EP1866289A1 (de) | Pyrimidincarbonsäure-derivate und ihre verwendung | |
| EP3983414B1 (en) | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| CN105829304B (zh) | N,n’取代哌啶胺类化合物、其制备方法及用途 | |
| HK40046949B (en) | Imidazopyridines useful as mitochondrial uncouplers | |
| HK40046949A (en) | Imidazopyridines useful as mitochondrial uncouplers | |
| TWI607995B (zh) | 氮雜環衍生物及其在藥物中的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |